RSS-Feed abonnieren
DOI: 10.1055/s-2001-11050
Osteoprotegerin-Ligand und Osteoprotegerin
Neue Konzepte in der Pathogenese und Therapie metabolischer KnochenerkrankungenPublikationsverlauf
Publikationsdatum:
31. Dezember 2001 (online)

Knochengewebe wird kontinuierlich durch einen koordinierten Prozess aus osteoklastärer Resorption und osteoblastärer Bildung erneuert, was zu einem dynamischen Gleichgewicht mit Erhaltung der strukturellen Integrität führt [39]. Einer inadäquat hohen Knochenresorption aufgrund einer gesteigerten Osteoklastenaktivität wird eine zentrale Bedeutung bei der Pathogenese vieler Knochenerkrankungen zugeschrieben, und die Hemmung dieses Prozesses ist ein wichtiges Therapieprinzip [39]. Die Entdeckung und Charakterisierung von Osteoprotegerin-Ligand (OPGL) [2] [27] [47], seines Rezeptors »Receptor activator of nuclear factor-κB« (RANK) [2] und seines Rezeptorantagonisten Osteoprotegerin (OPG) (siehe Glossar, [Tab. 1] [42] haben zu einem neuen, molekularen Konzept der Zellbiologie von Osteoklasten und des Knochenstoffwechsels geführt, in dem diese drei Komponenten eine essentielle Bedeutung einnehmen [18] [44] . In dieser Übersicht stellen wir die Grundlagen und die Regulation von OPGL und OPG durch Zytokine und Hormone dar und diskutieren die klinische Bedeutung dieses Systems für die Pathogenese und Therapie metabolischer Knochenerkrankungen.
Literatur
- 1
Akatsu T, Murakami T, Ono K. et al .
Osteoclastogenesis inhibitory factor exhibits
hypocalcemic effects in normal mice and in hypercalcemic nude mice
carrying tumors associated with humoral hypercalcemia of malignancy.
Bone.
1998;
23
495-498
MissingFormLabel
- 2
Anderson M A, Maraskovsky E, Billingsley W L. et al .
A homologue of the TNF receptor and its
ligand enhance T-cell growth and dendritic-cell function.
Nature.
1997;
390
175-179
MissingFormLabel
- 3
Bekker P J, Holloway D, Nakanishi A, Arrighi H M, Dunstan C R.
Osteoprotegerin
(OPG) has potent and sustained anti-resorptive activity in postmenopausal
women.
J Bone Miner Res.
1999;
14
1190
(Suppl 1)
MissingFormLabel
- 4
Bornefalk E, Dahlen I, Johannsson G, Ljunggren O, Ohlsson C.
Serum
levels of osteoprotegerin: Effects of glucocorticoids and growth
hormone.
Bone.
1998;
23
(Suppl 1)
F321
MissingFormLabel
- 5
Brown J M, Quinn J E, Buhler K R, Vessella R L.
Osteoprotegerin
and TRANCE are differentially expressed by prostate cancer cells
in vitro and in vivo.
J Bone Miner Res.
1999;
14
1085
(Suppl 1)
MissingFormLabel
- 6
Bucay N, Sarossi I, Dunstan C R. et al .
Osteoprotegerin-deficient mice
develop early onset osteoporosis and arterial calcification.
Genes
Dev.
1998;
12
1260-1268
MissingFormLabel
- 7
Burgess T L, Qian Y, Kaufman S. et al .
The ligand for osteoprotegerin (OPGL) directly
activates mature osteoclasts.
J Cell Biol.
1999;
145
527-538
MissingFormLabel
- 8
Capparelli C, Kostenuik P J, Morony S. et al .
Osteoprotegerin prevents and reverses hypercalcemia
in a murine model of humoral hypercalcemia of malignancy.
Cancer
Res.
2000;
60
783-787
MissingFormLabel
- 9
Dunstan C R, Capparelli C, Kelley M. et al .
Osteoprotegerin (OPG), a novel TNF-receptor
family member, profoundly inhibits endosteal bone resorption due
to growth, humoral hypercalcemia of malignancy, and interleukin
1.
J Bone Miner Res.
1997;
12
134
(Suppl 1)
MissingFormLabel
- 10
Fuller K, wong B, Fox S, Choi Y, Chambers T J.
TRANCE
is necessary and sufficient for osteoblast-mediated activation of
bone resorption in osteoclasts.
J Exp Med.
1998;
188
997-1001
MissingFormLabel
- 11
Gao Y -H, Shinki T, Yuase T. et al .
Potential role of cbfa1, an essential transcriptional
factor for osteoblast differentiation, in osteoclastogenesis: Regulation
of mRNA expression of osteoclast differentiation factor (ODF).
Biochem
Biophys Res Commun.
1998;
252
697-702
MissingFormLabel
- 12
Gori F, Hofbauer L C, Dunstan C R. et al .
The
expression of osteoprogerin and RANK ligand and the support of osteoclast
formation by stromal-osteoblast lineage cells is developmentally
regulated.
Endocrinology.
2000;
141
4768-4776
MissingFormLabel
- 13
Hofbauer L C, Dunstan C R, Spelsberg T C, Riggs B L, Khosla S.
Osteoprotegerin
production by human osteoblast lineage cells is stimulated by vitamin
D, bone morphegenetic protein-2, and cytokines.
Biochem
Biophys Res Commun.
1998;
250
776-781
MissingFormLabel
- 14
Hofbauer L C, Gori F, Riggs B L. et al .
Stimulation of osteoprotegerin ligand and
inhibition of osteoprotegerin production by glucocorticoids in human
osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced
osteoporosis.
Endocrinology.
1999;
140
4382-4389
MissingFormLabel
- 15
Hofbauer L C, Lacey D L, Dunstan C R, Spelsberg T C, Riggs B L, Khosla S.
Interleukin-1β and
tumor necrosis factor-α, but not interleukin-6 stimulate
osteoprotegerin ligand gene expression in human osteoblastic cells.
Bone.
1999;
35
255-259
MissingFormLabel
- 16
Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Spelsberg T C, Riggs B L.
Estrogen stimulates
gene expression and protein production of osteoprotegerin in human
osteoblastic cells.
Endocrinology.
1999;
140
4367-4370
MissingFormLabel
- 17
Hofbauer L C, Riggs B L, Dunstan C R, OBrien T, Khosla S.
Cyclosporin A
and glucocorticoids inhibit osteoprotegerin production in human
osteoblastic and coronary smooth muscle cells: Potential mechanism
for post-transplant osteoporosis and vascular disease.
J Bone
Miner Res.
1999;
14
(Suppl
1)
1174
MissingFormLabel
- 18
Hofbauer L C, Khosla S, Lacey D L, Dunstan C R, Boyle W J, Riggs B L.
The roles of
osteoprotegerin and osteoprotegerin ligand in the paracrine regulation
of bone resorption.
J Bone Miner Res.
2000;
15
2-12
MissingFormLabel
- 19
Horwood N J, Kartsogiannis V, Quinn J MW, Romas E, Martin T J, Gillepsie M T.
Activated
T cells support osteoclast formation in vitro.
Biochem
Biophys Res Commun.
1999;
265
144-150
MissingFormLabel
- 20
Horwood N J, Elliott J, Martin T J, Gillespie M T.
Osteotropic
agents regulate the expression of osteoclast differentiation factor
and osteoprotegerin in osteoblastic stromal cells.
Endocrinology.
1998;
139
4743-4746
MissingFormLabel
- 21
Hsu H, Lacey D L, Dunstan C R. et al .
Tumor
necrosis factor receptor family member RANK mediates osteoclast
differentiation and activation induced by osteoprotegerin ligand.
Proc
Natl Acad Sci USA.
1999;
96
3540-3545
MissingFormLabel
- 22
Jimi E, Akiyama S, Tsurukai T. et al .
Osteoclast
differentiation factor acts as a multifunctional regulator in murine
osteoclast differentiation and function.
J Immunol.
1999;
163
434-442
MissingFormLabel
- 23
Kong Y -Y, Yoshida H, Sarosi I. et al .
OPGL is a key regulator of osteoclastogenesis,
lymphocyte development and lymph-node organogenesis.
Nature.
1999;
397
315-323
MissingFormLabel
- 24
Kong Y -Y, Feige U, Sarosi I. et al .
Activated T cells regulate bone loss and
joint destruction in adjuvant arthritis through osteoprotegerin
ligand.
Nature.
1999;
402
304-309
MissingFormLabel
- 25
Kostenuik P J, Morony S, Capparelli C, Lacey D L, Dunstan C R.
Comparison
of the inhibitory effects of osteoprotegerin and of APD on PTHrP-mediated
hypercalcemia and bone remodeling.
J Bone Miner Res.
1999;
14
1135
(Suppl 1)
MissingFormLabel
- 26
Lacey D L, Timms E, Tan H -L. et al .
Osteoprotegerin (OPG) ligand is a cytokine
that regulates osteoclast differentiation and activation.
Cell.
1998;
93
165-176
MissingFormLabel
- 27
Lee S K, Lorenzo J A.
Parathyroid
hormone stimulates TRANCE and inhibits osteoprotegerin messenger
ribonucleic acid expression in murine bone marrow cultures: Correlation
with osteoclast-like cell formation.
Endocrinology.
1999;
140
3552-3561
MissingFormLabel
- 28
Li J, Sarosi I, Yan Y -Q. et al .
RANK
is the intrinsic hematopoietic cell surface receptor that controls
osteoclastogenesis and regulation of bone mass and calcium metabolism.
Proc
Natl Acad Sci USA.
2000;
97
1566-1571
MissingFormLabel
- 29
Lindberg M, Vidal O, Andersson N, Andersson K, Ryberg D, Ohlsson C.
Expression and regulation
of osteoprotegerin (OPG) and osteoclast differetiation factor (ODF)
in mice.
J Bone Miner Res.
1999;
14
F162
(Suppl 1)
MissingFormLabel
- 30
Lomaga M A, Yeh W -C, Sarosi I. et al .
TRAF6-deficiency results in osteopetrosis
and defective interleukin-1, CD40 and LPS signaling.
Genes
Dev.
1999;
13
1015-1024
MissingFormLabel
- 31
Lum L, Wong B R, Josien R. et al .
Evidence
for a role of a tumor necrosis factor-α (TNF-α)-converting
enzyme-like protease in shedding of TRANCE, a TNF family member
involved in osteoclastogenesis and dendritic cell survival.
J
Biol Chem.
1999;
274
13 613-13 618
MissingFormLabel
- 32
Manolagas S C, Jilka R L.
Bone marrow,
cytokines, and bone remodeling: Emerging insights into the pathophysiology
of osteoporosis.
N Engl J Med.
1995;
332
305-311
MissingFormLabel
- 33
Menaa C, Barsony J, Reddy S V, Cornish J, Cundy T, Roodman G D.
1,25-Dihydroxyvitamin
D3 hypersensitivity of osteoclast precursors from patients with
Pagets disease.
J Bone Miner Res.
2000;
15
228-236
MissingFormLabel
- 34
Morony S, Capparelli C, Lee R. et al .
A chimeric
form of osteoprotegerin inhibits hypercalcemia and bone resorption
induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2
D3.
J Bone Miner Res.
1999;
14
1478-1485
MissingFormLabel
- 35
Morony S, Capparelli C, Kostenuik P J. et al .
Osteoprotegerin
prevents osteolytic bone destruction in both athymic and syngeneic models
of experimental tumor metastassis to bone.
J Bone Miner Res.
1999;
14
1125
(Suppl 1)
MissingFormLabel
- 36
Nagai M, Sato N.
Reciprocal
gene expression of osteoclastogenesis inhibitory factor and osteoclast
differentiation factor regulates osteoclast formation.
Biochem
Biophys Res Commun.
1999;
257
719-723
MissingFormLabel
- 37
Neale S D, Itonga I, Smith R, Wass J, Athanasou N A.
Humoral
factors influencing osteoclast differentiation from circulating
mononuclear precursors in Pagets disease.
J Bone Miner
res.
1999;
14
SU433
(Suppl 1)
MissingFormLabel
- 38
Roodman G R.
Advances
in bone biology: The osteoclast.
Endocr Rev.
1996;
17
308-332
MissingFormLabel
- 39
Saika M, Inoue D, Kido S, Matsumoto T.
17β-Estradiol
stimulates expression of osteoprotegerin (OPG)/osteoclastogenesis
inhibitory factor (OCIF) by a mouse stromal cell line, ST-2.
J
Bone Miner Res.
1999;
14
F095
(Suppl 1)
MissingFormLabel
- 40
Shevde N K, Bendixen A C, Maruyama M, Pike J W.
Strogen inhibits RANKL
stimulated osteoclastogenesis in isolated murine myeloid progenitors
and the monocytic/macrophagic cell line RAW 264.7.
J Bone
Miner Res.
1999;
14
1070
(Suppl 1)
MissingFormLabel
- 41
Simonet W S, Lacey D L, Dunstan C R. et al .
Osteoprotegerin: A novel secreted protein
involved in the regulation of bone density.
Cell.
1997;
89
309-319
MissingFormLabel
- 42
Srivastava S K, Weitzmann M N, Chaudhari L R, Namba N, Pacifici R.
Estrogen
decreases the responsiveness of osteoclast precursors to OPGL by
down regulating OPGL induced JNK activity.
J Bone Miner Res.
1999;
14
1178
(Suppl 1)
MissingFormLabel
- 43
Suda T, Takahashi N, Udagawa N, Jimi E, Gillepsie M T, Martin T J.
Modulation
of osteoclast differentiation and function by the new members of
the tumor necrosis factor receptor and ligand families.
Endocr
Rev.
1999;
20
345-357
MissingFormLabel
- 44
Thomas R J, Guise T A, Yin J J. et al .
Breast cancer cells interact with osteoblasts
to support osteoclast formation.
Endocrinology.
1999;
140
4451-4458
MissingFormLabel
- 45
Tomoyasu A, Goto M, Fujise N. et
al .
Characterization of monomeric and homodimeric forms
of osteoclastogenesis inhibitory factor.
Biochem Biophys
Res Commun.
1999;
245
381-387
MissingFormLabel
- 46
Wong B R, Rho J, Arron J. et
al .
TRANCE is a novel ligand of the tumor necrosis
factor receptor family that activates c-jun N-terminal kinase in
T cells.
J Biol Chem.
1997;
272
25 190-12 194
MissingFormLabel
- 47
Huang L, Xu J, Wood D J, Zheng M H.
Gene
expression of osteoprotegerin ligand, osteoprotegerin, and receptor
activator of NF-κB in giant cell tumor of bone: Possible
involvement in tumor cell-induced osteoclast-like cell formation.
Am
J Pathol.
2000;
156
761-767
MissingFormLabel
- 48
Yamamoto M, Murakami T, Nishikawa M. et al .
Hypocalcemic effect of osteoclastogenesis
inhibitory factor/osteoprotegerin in the thyropara-thyroidectomized
rat.
Endocrinology.
1998;
139
4012-4015
MissingFormLabel
Korrespondenz
Dr. Lorenz C. Hofbauer
Abteilung für Gastroenterologie und EndokrinologieZentrum
für Innere MedizinPhilipps-Universität
Baldingerstraße
35033 Marburg
Telefon: 06421/286-2742
Fax: 06421/286-8922
eMail: hofbauer@post.med.uni-marburg.de